Dernières nouvelles
Information non disponible
- Bouaou, Ania MelissaEmployéania-melissa.bouaou@crchudequebec.ulaval.ca
Differential treatment effect between younger and older adults for new cancer therapies in solid tumors supporting US Food and Drug Administration approval between 2010 and 2021
Article de revueCancer, 129 (20), 2023.
Management of Oligometastatic Breast Cancer: An Expert Committee's Opinion
Article de revueCurr Oncol, 30 (2), 2023.
Perceived guideline clarity impacts guideline-concordant care for breast cancer screening in women age 40-49
Article de revueBMC Womens Health, 23 (1), 2023.
Determinants of guideline-concordant breast cancer screening by family physicians for women aged 40-49 years: a qualitative analysis
Article de revueCMAJ Open, 10 (4), 2022.
Fragility index of trials supporting approval of anti-cancer drugs in common solid tumours
Article de revueCancer Treat Rev, 94 , 2021.
Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience
Article de revueOncologist, 26 (4), 2021.
Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers
Article de revueJ Cancer, 12 (14), 2021.
Adjuvant Zoledronate Therapy for Women With Breast Cancer-Effective Treatment or Fool's Gold?
Article de revueJAMA Oncol, 7 (8), 2021.
Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations
Article de revueCancer Med, 10 (16), 2021.
Quantifying Withdrawal of Consent, Loss to Follow-Up, Early Drug Discontinuation, and Censoring in Oncology Trials
Article de revueJ Natl Compr Canc Netw, 19 (12), 2021.